Literature DB >> 26895813

Nutritional follow-up of patients after obesity surgery: best practice.

Mary O'Kane1, Julian H Barth1.   

Abstract

Obesity surgery is an appropriate treatment option for patients with severe and complex obesity and helps in the improvement of comorbidities. In the first 2 years following surgery, follow-up is provided by the obesity surgery centre. Ongoing care is then usually returned to the general practitioner. Patients need access to ongoing support and monitoring otherwise may be at risk of developing nutritional deficiencies such as anaemia or protein malnutrition. The British Obesity and Metabolic Surgery Society have developed guidelines on nutritional monitoring and nutritional supplements to support both bariatric centres and general practitioners. The Royal College of General Practitioners and BOMSS have worked collaboratively to develop Ten Top Tips for the management of obesity surgery patients to aid with the long-term management in primary care. Women, planning to get pregnant, need access to preconception advice and additional monitoring during pregnancy. It is essential that long-term data are collected and inputted into the National Bariatric Surgery Register. Obesity surgery improves comorbidities; however, patients must have access to long-term nutritional monitoring.
© 2016 John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2016        PMID: 26895813     DOI: 10.1111/cen.13041

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  2 in total

1.  Supplementation Adherence and Outcomes Among Pregnant Women After Bariatric Surgery.

Authors:  Silvia Leite Faria; Orlando Pereira Faria; Heloisa Rodrigues de Gouvêa; Angelica Amorim Amato
Journal:  Obes Surg       Date:  2019-01       Impact factor: 4.129

2.  Bilateral insufficiency hip fractures after bariatric surgery.

Authors:  V Barro; J H Nuñez; A Gargallo-Margarit; A Sallent; M Aguilar; A Hernandez
Journal:  Osteoporos Int       Date:  2016-12-23       Impact factor: 4.507

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.